- PROFESSOR Population Health Science and Policy
B.A., University of Chicago
M.S., Columbia University
M. Phil., Columbia University
Ph.D., Columbia University
- Director, Mount Sinai Center for Biostatistics
Director of Biostatistics of the International Center for Health Outcomes and Innovation Research (InCHOIR)
Professor, Population Health Science & Policy
Wang TT, Parides MK, Palese P. Seroevidence for H5N1 Influenza Infections in Humans: Meta-Analysis. Science 2012 Mar 23; 335(6075): 1463.
Smith PK, Michler RE, Woo YJ, Alexander JH, Puskas JD, Parides MK, Hahn RT, Williams JB, Dent JM, Ferguson TB Jr , Moquete E, Rose EA, Pagé P, Jeffries NO, O'Gara PT, Ascheim DD. Design, Rationale, and Initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: A Report from the Cardiothoracic Surgical Trials Network . J Thorac Cardiovasc Surg 2012 Jan; 143(1): 111-7.
Perrault LP, Moskowitz AJ, Kron IL, MD , Acker MA, Miller MA, Horvath KA, Thourani VH, Argenziano M, D’Alessandr DA, Blackstone EH, Moy CS, Mathew MD, Hung J, Gardner TJ, Parides MK. Optimal Surgical Management of Severe Ischemic Mitral Regurgitation: To Repair or to Replace? . Press, J Thorac Cardiovasc Surg 2011 Nov 3 ; [Epub ahead of print].
Gillinov AM, Argenziano M, Blackstone EH, Iribarne A, DeRose JJ, Ailawadi G, Russo MJ, Ascheim DD, Parides MK, Rodriguez E, Bouchard D, Taddei-Peters WC, Geller NL, Acker MA, Gelijns AC. Designing Comparative Effectiveness Trials of Surgical Ablation for Atrial Fibrillation: Experience of the Cardiothoracic Surgical Trials Network. J Thorac Cardiovasc Surg 2011 Aug; 142(2): 257-64 .
Mathew SJ, Vythilingam M, Murrough JW, Zarate CA Jr , Feder A, Luckenbaugh DA, Kinkead B, Parides MK, Trist DG, Bani MS, Bettica PU, Ratti EM, Charney DS. A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol 2011 Mar; 21(3): 221-9.
Mohr JP, Moskowitz AJ, Stapf C, Hartmann A, Lord K, Marshall SM, Mast H, Moquete E, Moy CS, Parides M, Pile-Spellman J, Al-Shahi Salman R, Weinberg A, Young WL, Estevez A, Kureshi I, Brisman JL. The ARUBA trial: current status, future hopes. Stroke 2010 Aug; 41(8): e537-40.Epub 2010 Jul 15.
Gelijns AC, Ascheim DD, Parides MK, Kent KC, Moskowitz AJ. Randomized trials in surgery. Surgery 2009 Jun; 145(6): 581-7.
Kaplan AS, Walsh BT, Olmsted M, Attia E, Carter JC, Devlin MJ, Pike KM, Woodside B, Rockert W, Roberto CA, Parides MK. The slippery slope: prediction of successful weight maintenance in anorexia nervosa. Psychol Med 2009 Jun; 39(6): 1037-45.
Burkhoff D, Parides MK, Borggrefe M, Abraham WT, Kadish A. "Responder analysis" for assessing effectiveness of heart failure therapies based on measures of exercise tolerance. J Card Fail 2009 Mar; 15(2): 108-15. Epub 2008 Dec 12.
Parides MK, Moskowitz AJ, Ascheim DD, Rose EA, Gelijns AC. Progress versus Precision: Challenges in Clinical Trial Design for Left Ventricular Assist Devices. The Annals of Thoracic Surgery 2006 Sep; 82(3): 1140-1146.
Walsh BT, Sysko R, Parides MK. Early response to desipramine among women with bulimia nervosa. Int J Eat Disord 2006 Jan; 39(1): 72-5.
Begg MD, Parides MK. Separation of individual-level and cluster-level covariate effects in regression analysis of correlated data. Statistics in Medicine 2003 Aug 30; 22(16): 2591-602.
Larson EL, Early E, Cloonan P, Sugrue S, Parides M. An organizational climate intervention associated with increased handwashing and decreased nosocomial infections. Behavioral Medicine 2000; 26(1): 14-22.
Namerow PB, Heywood GM, Windle JR, Parides MK. for the CABG Patch Trial Investigators and Coordinators. Quality of life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings of the CABG Patch Trial. Pacing and Clinical Electrophysiology 1999 Sep; 22(9): 1305-13 .
Bigger JT, Parides MK, Rolnitzky LM, Meier P, Levin B, Egan DA. Changes in Sample Size and Length of Follow-up to Maintain Power in the Coronary Artery Bypass Graft (CABG) Patch Trial. Controlled Clinical Trials 1998 Feb; 19(1): 1-14.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Parides did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Icahn (East) Building Floor 2 Room 14
1425 Madison Avenue
New York, NY 10029